Basilea Pharmaceutica Ltd.
https://www.basilea.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Basilea Pharmaceutica Ltd.
Physician Communication That Combined Results Of Unrelated Studies Gets Rebuke From US FDA
Althera’s misleading claims about its cholesterol drug Roszet is based on a ‘scientifically unsound analysis,’ OPDP tells company. FDA says studies cited in the pamphlet for doctors do not support claims regarding the magnitude of treatment effect.
Cardiovascular Catch-Up: Philips New AI Finds AF Needle In ECG Haystack; LimFlow Moves Closer To US Approval
Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small. Part two of this month's installment includes updates from lesser-known companies that you might have missed, including Cardiologs, Rhythm Management, LimFlow and ShockWave.
Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Basilea Bids Farewell To Oncology To Focus On Anti-Infectives
Derazantinib, a promising fibroblast growth factor kinase inhibitor, is one of the cancer assets the Swiss firm is preparing to sell off, either separately or in a bundle, as it focuses on anti-infectives.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Basilea Pharmaceutica AG